/* Style Definitions */
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:"Times New Roman";
Attend the 10th Annual Immunogenicity for Biotherapeutics May 4-6 in San Diego, CA, and bring back updates, new assay development and validation strategies, novel statistical analysis methods, risk management plans, and more, to your lab to help your company conserve time and money so you weather the storm in today’s economy. Join 100+ colleagues to hear the latest immuno techniques, including:
Assay Development and Validation Solutions
Industry scientists share case studies on immunogenicity assessment for preclinical, clinical, and post-marketing studies. Pfizer focuses on two case studies including development challenges for oligonucleotide therapeutics. Stryker Biotech, Biomarin Pharmaceuticals, Human Genome Sciences, and Zymogenetics share experiences in dealing with immunogenicity challenges including PEGylated enzyme therapeutics, target interference, and technical issues having a broad impact on testing.
Ligand Binding vs. Cell Based Assays
Hear four case studies on complexities of using ligand binding assays or cell based assays for neutralizing antibodies. Amylin Pharmaceuticals, Genentech, Eli Lilly, and Biogen Idec discuss the two platforms for Nabs assessment including sensitivity comparisons. Bring your questions and be ready to participate in our expert panel discussion to determine the best approach for your lab.
Less than two weeks to register! Book today to ensure your space!